A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

NT-KO-003

NT-KO-003 is a coated tablet, administered once a day

Trial Locations (17)

Unknown

Charité Universitätsmedizin, Berlin

Klinik und Poliklinik für Neurologie, Münster

Neurologisches Studienzentrum an der Stiftung Deutsche Klinik für Diagnostik GmbH, Wiesbaden

Hospital Germans Trias i Pujol, Badalona

Hospital Clinic i Provincial, Barcelona

Hospital del Mar, Barcelona

Hospital Vall d'Hebrón, Barcelona

Hospital Universitari Josep Trueta, Girona

Hospital Clínico San Carlos, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario La Princesa, Madrid

Hospital Universitario Puerta del Hierro, Madrid

Hospital Regional Universitario Carlos Haya, Málaga

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital Universitario La Fe, Valencia

Hospital Xeral Vigo, Vigo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Advancell - Advanced In Vitro Cell Technologies, S.A.

INDUSTRY

lead

Neurotec Pharma

INDUSTRY